Table 1.
Analysis | Studies, n | Patients, n | Incidence rate (per 1000 person-years) | I2, % | Q | P valuea |
---|---|---|---|---|---|---|
Studies that accounted for competing risk of death without HCC | 4 | 6542 | 9.96 (4.83–20.42) | 97.00 | <0.01 | |
Total | 16b | 148,157 | 8.29 (4.77–14.39) | 99.60 | <0.01 | |
HCC surveillance program | ||||||
No surveillance program | 9 | 145,212 | 4.82 (2.36–9.81) | 99.70 | <0.01 | .001a |
Surveillance program | 7 | 2945 | 18.59 (12.08–28.50) | 87.40 | <0.01 | |
Median study year | ||||||
Before 2000 | 7 | 101,871 | 4.99 (1.70–14.55) | 99.50 | <0.01 | .100 |
2000 and after | 9 | 46,286 | 12.58 (9.18–17.23) | 95.70 | <0.01 | |
Study setting | ||||||
Non–population-based | 9 | 134,197 | 10.91 (6.13–19.35) | 100.0 | <0.01 | .08 |
Population-based | 4 | 13,960 | 3.75 (1.31–10.65) | 99.00 | <0.01 |
HCC, hepatocellular carcinoma.
P value for comparison between subgroups.
Two studies provided time-to-event data for the cumulative incidence of HCC, but not data for incidence rates per 1000 person-years, hence they were not included in this analysis.